Retrospective Cohort Study
Copyright ©The Author(s) 2020 Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Table 5 Colectomy at 12 mo of vedolizumab therapy
Colectomy, nAustraliaOxfordP value
19/21013/930.25
Colectomy, nAnti-TNF naiveAnti-TNF exposedP value
9/18223/1210.0005
Colectomy, nPrimary LOSSecondary LOSP value
10/4523/610.795
VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss of response.
  • Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
  • URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428